- /
- Supported exchanges /
- NASDAQ /
- YMAB.NASDAQ
Y mAbs Therapeutics (YMAB NASDAQ) stock market data APIs
Y mAbs Therapeutics Financial Data Overview
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Y mAbs Therapeutics data using free add-ons & libraries
Get Y mAbs Therapeutics Fundamental Data
Y mAbs Therapeutics Fundamental data includes:
- Net Revenue: 84 553 K
- EBITDA: -23 352 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-08
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Y mAbs Therapeutics News
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?
We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stands against Caligan Partners' ot...
Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have done very well over the last year, with the share pric...
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Y-mAbs Therapeutics, Inc NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company
Key Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is sensitive to their trading actions 50% of the business is held by the top 9 shareholders Recent sal...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.